Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: A retrospective analysis

Journal of Nuclear Medicine

Volumn 52, Issue 11, 2011, Pages 1721-1726

  Biersack, Hans Jürgen ^a   Palmedo, Holger ^a   Andris, Andrej ^a   Rogenhofer, Stefan ^a   Knapp, Furn F ^b   Guhlke, Stefan ^a   Ezziddin, Samer ^a   Bucerius, Jan ^a   Von Mallek, Dirk ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

188Re HEDP; Bone metastases; Palliation; Prostate cancer; Survival

Indexed keywords

HYDROXYETHYLIDENEDIPHOSPHONATE RHENIUM RE 188; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RHENIUM 188; TUNGSTEN W 188; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CONTROLLED STUDY; DILUTION; DRUG DOSE ESCALATION; GENERATOR; GLEASON SCORE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ETIDRONIC ACID; FOLLOW-UP STUDIES; HORMONES; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80455127104     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.093674     Document Type: Article

References (32)

1. Cserháti P. Metastatic disease in breast cancer. J Clin Oncol. 1987;21:1235-1241.
2. StrumpfM. Krebbsschmerz. In: Zenz J, Jurna I, eds. Lehrbuch der Schmerztherapie. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft; 1993:427-436.
3. Kaplan E, Fels IG, Kotlowski BR. Therapy of carcinoma of the prostate metastatic to bone with P-32 labeled condensed phosphate. J Nucl Med. 1960;1:1-13.
4. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993;20:66-74. (Pubitemid 23015339)
5. Kutzner J, Dähnert W, Schreyer T, Grimm W, Brod KH, Becker M. Treatment of pain from bone metastases with 90Y [in German]. Nuklearmedizin. 1981;20:229-235. (Pubitemid 12233738)
6. Poner A, Mertens W. Strontium 89 in the treatment of metastatic prostate cancer. Can J Oncol. 1991;1:11-18.
7. Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med. 1989;15:49-54. (Pubitemid 19029835)
8. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J NuclMed. 1986;12:447-454. (Pubitemid 17037569)
9. Blake GM, Zivanovic MA, Lewington VJ. Measurements of the strontium plasma clearance rate in patients receiving Sr-89 radionuclide therapy. Eur J Nucl Med. 1989;15:780-783. (Pubitemid 20047228)
10. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med. 1987;13:41-46.
11. 153Sm] EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41-45.
12. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 1987;14:223-232.
13. Singh A, Holmes RA, Farhangi M. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
14. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646-651.
15. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27:123-130. (Pubitemid 30102016)
16. Maxon HR III, Schroder LE, Washburn LC, et al. Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med. 1998;39:659-663. (Pubitemid 28175844)
17. Schoeneich G, Palmedo H, Dierke-Dzierzon C, Müller SC, Biersack HJ. Rhenium-HEDP: palliative radionuclide therapy of painful bone metastases: preliminary results. Scand J Urol Nephrol. 1997;31:445-448.
18. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21:2869-2875. (Pubitemid 46621835)
19. Knapp FF Jr, Mirzadeh S, Beets AL, et al. Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot. 1998;49:309-315. (Pubitemid 28101659)
20. 99mTc]pertechnetate eluates from tungsten-188/rhenium-188 or (n,γ) produced molybdenum-99/technetium-99m generators to high specific volumes (12th International Symposium on Radiopharmaceutical Chemistry). J Labelled Comp Radiopharm. 1997:294-297.
21. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40:89-104.
22. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991;64:816-822.
23. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109:637-643. (Pubitemid 46190974)
24. Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol. 1996;19:102-107.
25. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392-400. (Pubitemid 40753745)
26. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26:2-7.
27. Maxon HR III, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32:1877-1881.
28. 186Re- etidronate in hormone- resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med. 2002;43:1150-1156.
29. 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med. 2000;41:647-654.
30. 186Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001; 66:101-109.
31. 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging. 2009; 36:1425-1433.
32. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging. 2008;35:756-765.